Mellozzan® (melatonin) approved in Turkey
EQL Pharma's key product Mellozzan® (tablets) has been approved for sale by the Turkish Medicines Agency. EQL's partner in Turkey, Abdi Ibrahim, will both manufacture and market Mellozzan® locally....
Press Releases
Exercise of warrants in EQL Pharma AB’s incentive programs
EQL Pharma AB (the ”Company“) today announces that two senior executives and one key employee in the Company have chosen to exercise 466,000 warrants in the Company’s outstanding incentive programs...
EQL Pharma's Chief Commercial Officer (CCO) sells shares to buy apartment for daughter
EQL Pharma's Chief Commercial Officer (CCO) Alexander Brising has recently sold shares for approximately SEK 2.1 million to pay for an apartment for his daughter who is starting university. "Not a ...
Bulletin from the annual general meeting in EQL Pharma AB on 21 August 2025
Regulatory
Today, on 21 August 2025, the annual general meeting was held in EQL Pharma AB. A summary of the adopted resolutions follows below.
The Nomination Committee’s proposal for the annual general meeting in EQL Pharma AB
Regulatory
Ahead of the annual general meeting on 21 August 2025 in EQL Pharma AB, the Nomination Committee has presented its proposal regarding the election of the board of directors. The Nomination Committe...